This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2000;283:317-321.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New Orleans—The concept that tailoring therapy to the specific molecular abnormality responsible for a disease will lead to safer and more effective drugs received a dramatic boost with results reported from a study of a new agent that targets the genetic flaw causing chronic myelogenous leukemia (CML).

In the study, reported here at the annual meeting of the American Society of Hematology, all 31 patients with CML who were given a daily pill containing at least 300 mg of a drug called STI-571 had a complete normalization of their blood counts, indicating a remission of the disease. At the same time, the drug, which targets a tyrosine kinase enzyme found only in the leukemia cells, appeared to eliminate all cells containing the chromosomal abnormality in three patients and substantially reduced the number of such cells in another eight, said Brian J. Druker, MD, of Oregon Health . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Wnt/{beta}-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer
Rao et al.
J. Clin. Endocrinol. Metab. 2006;91:159-168.
ABSTRACT | FULL TEXT  

The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
Podtcheko et al.
J. Clin. Endocrinol. Metab. 2003;88:1889-1896.
ABSTRACT | FULL TEXT